Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 12/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 1.00 |
| ▸ | RECQL | P46063 | 4/20 | 1.00 |
| ▸ | BLM | P54132 | 4/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 1.00 |
| ▸ | APEX1 | P27695 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | ESR1 | P03372 | 2/20 | 1.00 |
| ▸ | MCL1 | Q07820 | 2/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 2/20 | 1.00 |
| ▸ | NR4A1 | P22736 | 1/20 | 1.00 |
| ▸ | PTPN7 | P35236 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 4/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.62 |
| ▸ | PABPC1 | P11940 | 3/20 | 0.62 |
| ▸ | EIF4H | Q15056 | 3/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.62 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4728317 | 0.85 | POLB (0.73) | POLBTDP1RECQLBLMHSD17B10 | |
| SCHEMBL16907880 | 0.83 | POLB (0.70) | POLBTDP1RECQLBLMHSD17B10 | |
| SCHEMBL19662992 | 0.81 | POLB (0.68) | POLBTDP1RECQLBLMHSD17B10 | |
| SCHEMBL22129205 | 0.80 | POLB (0.66) | POLBTDP1RECQLBLMHSD17B10 | |
| SCHEMBL17207997 | 0.79 | KDM4E (0.65) | POLBTDP1RECQLBLMHSD17B10 | |
| SCHEMBL16907925 | 0.79 | POLB (0.65) | POLBTDP1RECQLBLMHSD17B10 | |
| SCHEMBL24367842 | 0.78 | POLB (0.64) | POLBTDP1RECQLBLMHSD17B10 | |
| SCHEMBL21237318 | 0.78 | POLB (0.64) | POLBTDP1RECQLBLMHSD17B10 | |
| SCHEMBL835316 | 0.78 | PARP1 (0.79) | POLBTDP1RECQLBLMHSD17B10 | |
| SCHEMBL1468153 | 0.78 | POLB (0.64) | POLBTDP1RECQLBLMHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105240-A1 | Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2009-04-23 | — | — | US | claimed |
| US-20120095032-A1 | METHODS FOR TREATING LEUKEMIA AND MYELODYSPLASTIC SYNDROME, AND METHODS FOR IDENTIFYING AGENTS FOR TREATING SAME | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2012-04-19 | — | — | US | disclosed |
| US-20120095032-A1 | METHODS FOR TREATING LEUKEMIA AND MYELODYSPLASTIC SYNDROME, AND METHODS FOR IDENTIFYING AGENTS FOR TREATING SAME | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2012-04-19 | — | — | US | disclosed |
| US-20120095032-A1 | METHODS FOR TREATING LEUKEMIA AND MYELODYSPLASTIC SYNDROME, AND METHODS FOR IDENTIFYING AGENTS FOR TREATING SAME | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2012-04-19 | — | — | US | disclosed |
| US-20090118135-A1 | METHODS AND COMPOUNDS FOR REGULATING APOPTOSIS | THE BURNHAM INSTITUTE (US) | 2009-05-07 | — | — | US | disclosed |
| US-20090118135-A1 | METHODS AND COMPOUNDS FOR REGULATING APOPTOSIS | THE BURNHAM INSTITUTE (US) | 2009-05-07 | — | — | US | disclosed |
| US-20090105240-A1 | Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2009-04-23 | — | — | US | disclosed |
| US-20090105240-A1 | Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105240-A1 | Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same | MCL1, AS3MT, MYADM | POLB 819/4885TDP1 1293/4885RECQL 269/4885 |
| US-20090118135-A1 | METHODS AND COMPOUNDS FOR REGULATING APOPTOSIS | BCL2, BAX, BAD | POLB 1539/4885TDP1 2043/4885RECQL 3059/4885 |
| US-20120095032-A1 | METHODS FOR TREATING LEUKEMIA AND MYELODYSPLASTIC SYNDROME, AND METHODS FOR IDENTIFYING AGENTS FOR TREATING SAME | MCL1, AS3MT, MYADM | POLB 819/4885TDP1 1293/4885RECQL 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.